TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Blade Air Mobility ( (BLDE) ) has provided an announcement.
On August 29, 2025, Blade Air Mobility, now known as Strata Critical Medical, Inc., completed the sale of its Passenger business to Joby Aero, Inc. for approximately $76 million, with potential additional earnings based on future performance targets. This transaction marks a strategic shift for the company, which will now focus on its medical transport services, as evidenced by the new commercial agreement with Joby Buyer. Additionally, the company has undergone significant leadership changes with the appointment of Melissa Tomkiel and William Heyburn as co-Chief Executive Officers, and a rebranding initiative, including a name change and new Nasdaq ticker symbol ‘SRTA’.
The most recent analyst rating on (BLDE) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Blade Air Mobility stock, see the BLDE Stock Forecast page.
Spark’s Take on BLDE Stock
According to Spark, TipRanks’ AI Analyst, BLDE is a Neutral.
Blade Air Mobility’s overall score is primarily driven by the positive strategic shift highlighted in the earnings call, focusing on the Medical division’s growth. However, financial performance challenges, including negative profitability and cash flow issues, weigh down the score. Technical indicators provide a balanced outlook, while valuation remains a concern due to negative earnings.
To see Spark’s full report on BLDE stock, click here.
More about Blade Air Mobility
Average Trading Volume: 1,126,547
Technical Sentiment Signal: Buy
Current Market Cap: $386.4M
See more insights into BLDE stock on TipRanks’ Stock Analysis page.